Qiagen 被私募股权公司 EQT 以 121 亿美元收购
Qiagen agrees to private equity takeover
Qiagen 宣布同意被 EQT 私募股权公司以 108 亿欧元(约 121 亿美元)收购,包括约 11 亿美元债务。新任 CEO Jonathan Pratt 表示,私有化将使公司更灵活地投资并实现长期战略。交易预计在 2027 年中完成,需股东和监管批准。
An article from
Dive Brief
EQT Private Equity has agreed to pay about $12.1 billion, including debt, for the diagnostics company, which has long been the subject of takeover speculation.
Published Oct. 23, 2026
By
This audio is auto-generated. Please let us know if you have feedback.
Dive Brief:
- Qiagen said Wednesday it has agreed to a takeover offer from EQT Private Equity valued at 10.8 billion euros (about $12.1 billion), including approximately $1.1 billion of debt.
- The agreement comes less than two months after the testing company, long a rumored takeover target, installed Jonathan Pratt as its new CEO. Six years ago, Thermo Fisher Scientific was set to buy Qiagen, but the deal fell apart after shareholders objected to the price.
- William Blair analysts, in a Thursday note, said EQT’s all-cash offer of 46.50 euros per share (about $52.20) was reasonable, given Qiagen’s relatively lower growth profile.
Dive Insight:
EQT’s offer represents a premium of roughly 40% to Qiagen’s closing share price of 33.15 euros on the Frankfurt-based Xetra electronic trading system on July 8, the last trading day before reports of takeover interest from private equity firms were published, Qiagen said.
The company said its supervisory board and managing board, following a review of strategic options, agreed to recommend accepting EQT’s offer and fully support the transaction. The review included discussions with both strategic and financial parties.
Qiagen said it will gain greater flexibility to invest for the long term under private ownership and be better positioned to deliver on its full potential.
“Under private ownership, we can move faster and have greater freedom to put resources behind the most attractive opportunities that align best with our long-term strategy. That can help us grow the business in line with our priorities,” said Pratt.
The deal price implies about 15 times William Blair’s estimate for 2027 earnings before interest, tax, depreciation and amortization. That is below comparable life sciences transactions generally in the high teens to low 20s, the analysts said.
“There is plenty to like about Qiagen’s core portfolio,” the William Blair analysts said. “However, broader-based growth has remained elusive, with gains in some businesses offset by headwinds elsewhere.”
EQT agreed to support Qiagen’s long-term development, including commitments related to its strategy, business, key brands, operational footprint, R&D activities, employee arrangements and financing. The company will continue to operate under the Qiagen name.
The deal is expected to close in mid-2027, subject to Qiagen shareholder and regulatory approvals.
来源:MedTech Dive 器械媒体 · medtechdive.com